A system and method for detecting and verifying bradycardia/asystole episodes includes sensing an electrogram (EGM) signal. The EGM signal is compared to a primary threshold to sense events in the EGM signal, and at least one of a bradycardia or an asystole is detected based on the comparison. In response to detecting at least one of a bradycardia or an asystole, the EGM signal is compared to a secondary threshold to sense events under-sensed by the primary threshold. The validity of the bradycardia or the asystole is determined based on the detected under-sensed events.

An optical isolation element is provided on an optical sensor comprising a light source, at least one photodetector, and indicator material that emits light that is detected by the photodetector when optically excited by the light source. The optical isolation element limits the optical paths by which light may be transmitted by the light source, thereby limiting exposure of the excitation light source to regions of interest. The optical isolation element also limits the optical paths by which light may be transmitted to the photodetector, thereby limiting exposure of the photodetector to light from extraneous sources.

Ingestible devices with a relatively large payload volume or sample volume, as well as related components, systems and methods, are disclosed.

Systems and methods are described for providing power transfer between modular intraluminal devices. A system embodiment includes, but is not limited to, a first intraluminal device and a second intraluminal device; the first intraluminal device including a body structure, a sensor, a processor, a data transmitter, and a wireless energy receiver oriented to wirelessly receive energy originating external to the first intraluminal device to power at least one of the sensor, the processor, or the data transmitter; the second intraluminal device including a second body structure, and an energy storage device configured to wirelessly transfer energy stored in the energy storage device to the wireless energy receiver of the first intraluminal device when the first intraluminal device and the second intraluminal device are positioned within a subject.

Systems and methods are described for providing power transfer between modular intraluminal devices. A system embodiment includes, but is not limited to, a first intraluminal device and a second intraluminal device; the first intraluminal device including a body structure, a sensor, a processor, a data transmitter, and an energy storage module configured to power at least one of the sensor, the processor, or the data transmitter; the second intraluminal device including a second body structure, an energy storage device, and a docking structure, where the energy storage device is configured to transfer energy when the first intraluminal device and the second intraluminal device are coupled via the docking structure, the docking structure further configured to automatically decouple the first intraluminal device and the second intraluminal device subsequent to transfer of the energy.

A body-mountable device is provided to facilitate communication, via in-body electrical signals transmitted via electrodes of the body-mountable device into fluid of the body, with a smart pill located in a gastrointestinal tract of a body to which the body-mountable device is mounted or with some other device located within the body. The body-mountable device can be a contact lens or other eye-mountable device such that the electrodes of the eye-mountable device can transmit in-body electrical signals via tear fluid. The body-mountable device could transmit a command to the smart pill to dispense a drug into the body. The smart pill could transmit, via in-body electrical signals, an indication of a detected property of the gastrointestinal tract to the body-mountable device. A latency of transmission of signals between the body-mountable device and the smart pill could be used to determine the location of the smart pill within the gastrointestinal tract.

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TLR agonist.

The present invention relates to miniature biosensor technology which can be directly embedded into medical device technology to create a new category of multifunctional smart medical devices. The resulting data from these smart medical devices results in wireless communication networks and standardized referenceable databases, which are used in the creation of best practice guidelines, clinical decision support tools, personalized medicine applications, and comparative technology assessment.

In alternative embodiments, the invention provides compositions such as devices, pills, beads, capsules, products of manufacture, particles, microparticles, nanoparticles, gels, liquid gels, liquid gel capsules, capsules, tablets, geltabs, liquids, sprays, emulsions, suspensions, pastes or yogurts, for the detection and isolation of biomarkers, nucleic acids, proteins or peptides, proteoglycans, lipids, fats, sugars or polysaccharides in the gastrointestinal tract for e.g., detecting the presence of particular exogenous or endogenous nucleic acids, e.g., DNA or RNA, or proteins, in the gastrointestinal tract, for example, to diagnose the presence of an infectious or exogenous agent such as a virus, a fungus, a parasite, a bacteria, intestinal helminths and protozoan parasites, and the like, or a biomarker such as a cancer-causing or cancer-predisposing allele, e.g., mutations of the KRAS2 oncogene in pancreatic cancer. In alternative embodiments, compositions of the invention comprise magnetic particles such as a magnetically-responsive microparticle or nanoparticle; a superparamagnetic bead or polystyrene bead; a superparamagnetic fine particle; a ferrimagnetic particle; or, a magnetic microsphere, nanosphere, microbead or nanobeads. In alternative embodiments, the invention provides methods for detecting, retrieving, capturing or isolating a sample of a nucleic acid, or an anionic, cationic or hydrophobic protein or peptide, a mucin, a phosphoprotein, a proteoglycan or a polysaccharide, in vivo.

An implantable intraocular physiological sensor for measuring a physiological characteristic, such as intraocular pressure. The implantable intraocular physiological sensor may include a tubular main body configured to house one or more electrical components. The implantable intraocular physiological sensor may also include a sensor cap configured to be inserted into a first end of the tubular main body with a moisture barrier seal. The implantable intraocular physiological sensor may wirelessly transmit measurements to an external device.